Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BNTX
SellBioNTech SE · Healthcare · Germany · $25.6B · Avg Vol: $151M/d
COMPANY DESCRIPTION
BioNTech SE is a German biotechnology company specializing in the development of active immunotherapies for cancer and other serious diseases, famously co-developing an mRNA-based COVID-19 vaccine with Pfizer. The company's competitive moat stems from its pioneering mRNA technology platform, robust intellectual property, and diversified pipeline of therapies across oncology, infectious diseases, and rare conditions. BioNTech is a global leader in mRNA innovation, pursuing personalized treatment approaches.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.1B | 4.4B | 3.2B | 3.3B | -45.1% | 3.1B | 2.1B | 2.1B | -19.8% |
| EPS | 44.94 | 4.48 | -3.21 | -5.45 | -90.0% | -7.84 | -5.75 | -5.63 | — |
| Shares | 243.2M | 237.7M | 240.0M | 251.3M | +3.3% | 251.2M | — | — | — |
| Debt | 245.9M | 253.9M | 294.6M | 309.8M | 8.0% | 368.8M | — | — | — |
| Equity | 23.2B | 23.5B | 22.5B | 22.3B | -1.4% | — | — | — | — |
| Op CF | 15.7B | 6.2B | 240.7M | 528.4M | -67.7% | 792.9M | — | — | — |
| Inv CF | -40.9M | -8.1B | -2.4B | -2.9B | — | — | — | — | — |
| Fin CF | -1.6B | -902.2M | -53.2M | -61.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BNTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BNTX | BioNTech SE(you) | $25.6B | 28 | Sell |
| IMTX | Immatics N.V. | $1.4B | 11 | Strong Sell |
| FYB.DE | Formycon AG | $380M | 36 | Hold |
| IFRX | InflaRx N.V. | $329M | 39 | Hold |
| VRXA | Veraxa Biotech AG | $191M | 1 | Strong Sell |
| SRT3.DE | Sartorius Aktiengesellschaft | $19.6B | 55 | Hold |
| SHL.DE | Siemens Healthineers AG | $52.7B | 62 | Hold |
| FRE.DE | Fresenius SE & Co. KGaA | $25.5B | 82 | Strong Buy |
| BAYN.DE | Bayer Aktiengesellschaft | $55.6B | 81 | Strong Buy |
| MRK.DE | Merck KGaA | $70.2B | 85 | Strong Buy |
Peer medians: ROE 7.2% · P/E 16.5x · Gross margin 42.9%